Future Medicinal Chemistry is published 16 issues per year in print and online formats on a rapid publication basis, with articles subject to peer review by three independent assessors. The journal has an international expert authorship and offers commentary and analysis on the advances and current research in medicinal chemistry.
Coverage of the journal is overseen by two Senior Editors and an extensive international advisory panel. The two Senior Editors are Iwao Ojima, Director of institute of Chemical Biology and Drug Discovery, Stony Brook University, USA and David Thurston, Head of the department of Pharmaceutical and Biological Chemistry, University of London, UK
Senior Editor Iwao Ojima said “This is great news for the medicinal chemistry community. Future Medicinal Chemistry fills an unmet niche and with wider coverage provided by MEDLINE®, it will truly globalize its appeal. Future Medicinal Chemistry will play a major role in the harmonization of both regulatory guidelines and science in the field of medicinal chemistry.”
Elisa Manzotti, Editorial Director of the Future Medicine series commented, “We are delighted that Future Medicinal Chemistry has been accepted for inclusion and will work with the Senior Editors of the journal to ensure that future issues of Future Medicinal Chemistry keep pace with the huge amount of research being generated.” She continued: “We would like to thank our Senior Editors and Editorial Board for their hard work, intellectual input and guidance in targeting and evaluating topical, pioneering content to ensure inclusion of the journal by MEDLINE.”
Access to Future Medicinal Chemistry is available on a FREE 30-day trial basis. To apply for your free trial please email info@future-science.com quoting reference FMCPR11 to obtain password access.
For further information please contact:
Craig Canham, Corporate Public Relations, Future Science Group
T: +44 (0) 20 8371 6092
F: +44 (0) 20 8343 2313
E: c.canham@future-science.com
ABOUT FUTURE MEDICINAL CHEMISTRY (www.future-science.com/loi/fmc)
Future Medicinal Chemistry provides a monthly point of access to commentary and debate for this ever-expanding and diversifying community. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research-from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.
There has never been more pressure to produce potent and safe compounds faster and more efficiently. Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
Topics covered include:
• Drug discovery technologies
• Design and synthesis of novel lead compounds
• Computational approaches to synthesis and modelling
• Biophysical techniques for structural characterization
• Overviews of novel therapeutic strategies and emerging targets
• Drug targeting and delivery
• ADME/Tox investigations
• Commentary on science policy, economic and IP issues
ABOUT FUTURE SCIENCE GROUP
The Future Science Group (www.future-science-group.com) is an expanding group of independent publishing companies active in the field of scientific information and endeavor, including Expert Reviews Ltd (formerly known as Future Drugs Ltd) Future Medicine Ltd and Future Science Ltd. As a leading provider of products and services for the medical, science and business communities, we present the most important scientific breakthroughs in an accessible and evaluated format, while at the same time providing the scientific community with uniq ue vehicles for disseminating forward-thinking research information and data. Future Medicine provides cutting-edge coverage of postgenomic medicine. Our publications provide healthcare practitioners and research professionals with a unique source of original research and topical reviews. Complete listings of titles under each imprint are available at www.expert-reviews.com, www.futuremedicine.com and www.future-science.co m.
